Invitation to presentation of Bactiguard’s interim report on November 14

Bactiguard Holding AB publishes the interim report for the third quarter on Friday 14 November at 08:00 CET

In connection with this, a conference call for analysts and media will be held at 10:00 CEO on November 14. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions.

The report will be available at Bactiguard’s website www.bactiguard.com from 08:00 CET the same day.

To participate in the conference call, please dial +46 8 519 990 30


For further information, please contact:
Cecilia Edström, Director of Communications
mobile: +46 722 262 328; e-mail: cecilia.edstrom@bactiguard.com

For questions about participation in the conference call, please contact:
These Sundevall, Tfn: +46 8 440 58 69 e-mail: these.sundevall@bactiguard.se

About Bactiguard

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare-related infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare-associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013 and has 60 employees, headquarters in Stockholm and production facilities in Sweden and Malaysia. The Bactiguard share is listed on Nasdaq Stockholm. Read more at: www.bactiguard.se

Tags:

About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

Subscribe

Documents & Links